Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-14

Cannabis Bioscience International Holdings, Inc. (CBIH) Stock Forecast Oct. 14, 2026

Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC

Follow Unlock full AI forecasts
Rating · 90D ▼ Bearish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Bottom 35% of 4004 stocks scored
Rank correlation · 90D n/a No per-ticker sample yet
Market Cap n/a
Summary

Cannabis Bioscience International Holdings, Inc. (CBIH) stock forecast summary

Our AI ranks Cannabis Bioscience International Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Its market capitalization is not available, so no size classification is given. Its Current Ratio of 0.00x is the lowest of the 16 peers that report one.

A per-ticker accuracy statistic for CBIH is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, CBIH included.

Follow CBIH free
Price

CBIH price chart and AI forecast

CBIH
Cross-section · 2026-10-14

How CBIH ranks among 4004 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals

Cannabis Bioscience International Holdings, Inc. (CBIH) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.

Valuation & Market

MetricCBIHIndustry medianRank
EPS $0.00 – –

Profitability & Margins

MetricCBIHIndustry medianRank
ROA -31398.1% -19.3% 13/13
ROIC 32.3% 7.6% 3/12
Gross Margin 60.3% 33.0% 3/7
Operating Margin -379.5% -125.8% 10/13
Net Margin -467.9% -114.8% 9/11
EBT Margin -379.5% -114.8% 10/13
Tax Rate 0.0% – –

Financial Health

MetricCBIHIndustry medianRank
Current Ratio 0.00x 0.78x 16/16
Interest Coverage -2.7x -2.7x 7/13
Working Capital -$1M -$1M 8/15

Cash Flow

MetricCBIHIndustry medianRank
Operating Cash Flow -$280K -$280K 8/15

Income Statement

MetricCBIHIndustry medianRank
Operating Income $0.00M $0.00M 7/15
Net Income $0.00M $0.00M 5/13
Cost of Goods Sold $40K $4M 8/8

Balance Sheet Highlights (USD millions)

Total Current Assets$0.00M
Cash & Short-term Investments$0.00M
Accounts Receivable$0.00M
Total Liabilities$1M
Quarterly Financial Reports

CBIH quarterly financials and insider trading

Industry Peers · Services-Commercial Physical & Biological Research

Cannabis Bioscience International Holdings, Inc. (CBIH) industry peers

Companies classified under the same SEC industry code as Cannabis Bioscience International Holdings, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
CBIH Cannabis Bioscience International Holdings, Inc. ▼ N/A – –
IQV Iqvia Holdings Inc. ▼ $43.51B 32.6x 7.3x
INCY Incyte Corp ▼ $21.70B 17.5x 4.5x
MEDP Medpace Holdings, Inc. ▶ $17.02B 34.6x 39.2x
CRL Charles River Laboratories International, Inc. ▶ $14.27B – 5.0x
ICLR Icon Plc ▶ $12.68B – 1.4x
ABSI Absci Corp ▲ $1.56B – 7.9x
OABI Omniab, Inc. ▲ $683M – 2.6x
NRC Nrc Health ▲ $446M – –
MXCT Maxcyte, Inc. ▲ $100M – 0.6x
ONMD Onemednet Corp ▶ $24M – –
VSBC Vitaspring Biomedical Co. Ltd. ▼ $7M – –
BUDZ Weed, Inc. ▲ $3M – –
BIAF Bioaffinity Technologies, Inc. ▼ N/A – –
FOXO Foxo Technologies Inc. ▼ N/A – –
ISPC Ispecimen Inc. ▼ N/A – –

Where CBIH sits on the market map

Industrial Applications and Services · Services-Commercial Physical & Biological Research
Explore the map →
News

Cannabis Bioscience International Holdings, Inc. (CBIH) stock news

Loading...

FAQ

Cannabis Bioscience International Holdings, Inc. (CBIH) stock forecast FAQ

What is the Cannabis Bioscience International Holdings, Inc. (CBIH) stock forecast?

Our AI ranks Cannabis Bioscience International Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Cannabis Bioscience International Holdings, Inc. stock predictions?

A per-ticker accuracy statistic for CBIH is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Cannabis Bioscience International Holdings, Inc. forecasts updated?

Cannabis Bioscience International Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.

Which companies are Cannabis Bioscience International Holdings, Inc.'s industry peers?

16 issuers in our coverage, CBIH included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.